Tracked deals
14
14 tracked deals across 2019-2026.
Biotechnology Buyers & Acquisitions in Florida
Buyer mix
Strategic-led
11 strategic · 4 pe
Top trend
Volume peaked in 2023
4 tracked deals announced in 2023.
Primary Insight
What Stands Out
- Strategic consolidation of development and commercialization: Telomir’s acquisition of TELI Pharmaceuticals, Inc. makes Telomir the sole holder of global rights to Telomir-1 (Telomir-Zn).
- Capability-building through operating assets: deals add or integrate lab, analytical, delivery, extraction/cultivation, and/or GMP or manufacturing capacity—such as Branded Legacy’s additions via All In Extracts and Arranta’s Gainesville Center of Excellence.
- Clinical and research enablement appears repeatedly: examples include Zephyr AI’s acquisition of oncology scientific/clinical intelligence (Aster Insights) and Boca Biolistics’ positioning as a CRO and biobanking/biomaterials provider.
- Stock- and merger-based structures are common in the record: Cyclo’s all-stock merger and other stock-consideration transactions (including reported stock-deal structuring) appear alongside cash/tender components.
- Florida is the geographic hub: each transaction listed is tied to “Florida, United States,” with several featuring Florida-based teams, facilities, or ongoing operations.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Find buyers like these for your dealBuyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| Branded Legacy, Inc. | 2 | OTC-listed pharmaceutical biotechnology company operating... | Strategic |
| Arcline Investment Management | 1 | Growth-oriented private equity firm focused on platform i... | PE |
| Arranta Bio | 1 | Contract development and manufacturing organization (CDMO... | Strategic (PE-backed) |
| Blue Water Ventures International, Inc. | 1 | Publicly-listed company historically focused on shipwreck... | Strategic |
| Clairvest Equity Partners VI (CEP VI) | 1 | Clairvest-managed co-investment fund (CEP VI) participati... | PE |
| Clairvest Group Inc. | 1 | Toronto-based publicly listed private equity firm that ma... | PE |
| Cyclo Therapeutics, Inc. | 1 | Clinical-stage biotechnology company developing Trappsol ... | Strategic |
| Fifty 1 Labs, Inc. | 1 | Publicly traded (OTC) life‑sciences / biotech company pur... | Strategic |
| Lobe Sciences Ltd. | 1 | North American biopharmaceutical company focused on devel... | Strategic |
| Medix Biochemica | 1 | Supplier and manufacturer of critical raw materials (anti... | Strategic |
Acquisition Volume in Biotechnology in Florida by Year
Last 6 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
July 31, 2026
- Buyer
- Processa Pharmaceuticals, Inc.
- Target
- Vidya Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- Florida, United States
- Type
- Buyout
Processa Pharmaceuticals acquired Vidya Therapeutics in a stock-for-stock transaction to bring Vidya’s CNS-penetrant, once-daily BTK inhibitor VT-7208 into Processa’s pipeline. Concurrently, Processa entered into a definitive agreement for an approximately $200 million private placement, with proceeds intended to fund VT-7208’s parallel Phase 2 proof-of-concept studies across food allergy, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis (RMS).
-
- Buyer
- Telomir Pharmaceuticals, Inc.
- Target
- TELI Pharmaceuticals, Inc.
- Seller
- Certain former TELI shareholders (received milestone-based contributions and Telomir stock)
- Industry
- Biotechnology
- Location
- Florida, United States
- Type
- Buyout
Telomir Pharmaceuticals completed its previously announced stock-for-stock acquisition of TELI Pharmaceuticals. The deal makes Telomir the sole holder of global rights to Telomir-1 (Telomir-Zn), consolidating worldwide development and commercialization under one structure.
-
August 26, 2025
- Buyer
- Zephyr AI, Inc.
- Target
- Aster Insights
- Industry
- Biotechnology
- Location
- Florida, United States
- Type
- Buyout
Zephyr AI has acquired Aster Insights, a provider of scientific and clinical intelligence for oncology discovery, making Aster a wholly owned subsidiary to deepen Zephyr's real-world evidence and oncology data capabilities. Concurrently, Zephyr appointed Dr. Allen Chao, founder of Watson Pharmaceuticals, as CEO to lead the combined company's expansion of AI-driven precision medicine and clinical trial optimization.
-
March 20, 2025
- Buyer
- Fifty 1 Labs, Inc.
- Target
- Genetic Networks LLC
- Industry
- Biotechnology
- Location
- Florida, United States
- Type
- Buyout
Fifty 1 Labs, Inc. (OTC: FITY) has acquired Genetic Networks LLC in a transaction announced March 2025; several press releases indicate the deal was structured as a stock consideration (one report cites a $10 million stock deal). 4Cable TV International, Inc. (OTC: CATV) facilitated the transaction as part of its reverse-merger preparations and announced a related dividend for CATV shareholders; Fifty 1 Labs said the acquisition positions it to pursue expanded biotech capabilities and potential multi-million-dollar DoD contracts.
-
January 9, 2024
- Buyer
- Branded Legacy, Inc.
- Target
- All In Extracts LLC
- Industry
- Biotechnology
- Location
- Florida, United States
- Type
- Buyout
Branded Legacy, Inc. (OTC.PK: BLEG), a Melbourne, Florida–based pharmaceutical biotechnology company, has completed the acquisition of All In Extracts LLC, a Tampa, Florida–based medicinal ethnobotany and botanical extracts manufacturer. The deal adds proprietary delivery systems, lab and cultivation capacity (including 800 sq ft of lab space and 16 acres of grow space) to Branded Legacy’s subsidiaries and supports product and capability expansion into supplements and related health-and-wellness markets.
-
December 27, 2023
- Buyer
- Cyclo Therapeutics, Inc.
- Target
- Applied Molecular Transport Inc.
- Seller
- Applied Molecular Transport stockholders
- Industry
- Biotechnology
- Location
- Florida, United States
- Type
- Buyout
Cyclo Therapeutics completed an all-stock merger with Applied Molecular Transport (AMT), with AMT shareholders receiving 0.1331 shares of Cyclo Therapeutics for each AMT share (approximately 5,822,720 Cyclo shares, or ~18% of the combined company). The combined, Nasdaq-listed company will operate as Cyclo Therapeutics, focus on advancing the Phase 3 TransportNPC study of Trappsol Cyclo for Niemann-Pick Disease Type C1, be led by Cyclo's existing management and headquartered in Gainesville, Florida.
-
December 4, 2023
- Buyer
- Branded Legacy, Inc. (BLEG)
- Target
- MariJ Pharmaceuticals, Inc.
- Seller
- Rick Pertile (CEO of MariJ Pharmaceuticals, Inc.)
- Industry
- Biotechnology
- Location
- Florida, United States
- Type
- Buyout
Branded Legacy, Inc. (OTC: BLEG) completed the acquisition of MariJ Pharmaceuticals, Inc., a Clearwater, Florida-based certified-organic CBD extraction and production company, on December 4, 2023. The deal transfers MariJ's mobile CO2 extraction units, licensed vehicles, production lab, IP (including a patent), organic certifications, customer and operational databases, and licenses to Branded Legacy in exchange for preferred series stock and cash.
-
August 30, 2023
- Buyer
- Lobe Sciences Ltd.
- Target
- Altemia & Company, LLC
- Seller
- Altemia & Company, LLC, Altemia members (Selling Members)
- Industry
- Biotechnology
- Location
- Florida, United States
- Type
- Buyout
Lobe Sciences Ltd. signed an amendment to its share purchase agreement to acquire a 100% interest in Altemia & Company, LLC, including assets, know‑how, IP and commercial inventory related to Altemia, a medical food for sickle cell disease. The amended terms provide for the return and milestone-based reissuance of 76,000,000 Lobe common shares to the Altemia selling members upon achievement of specified development, delivery, commercial sale and tech-transfer milestones.
-
February 21, 2023
- Buyer
- Clairvest Group Inc., Clairvest Equity Partners VI (CEP VI)
- Target
- Boca Biolistics
- Industry
- Biotechnology
- Location
- Florida, United States
- Type
- Growth capital
Clairvest Group Inc., together with its Clairvest Equity Partners VI co-investment pool, made a US$25 million equity investment in Boca Biolistics, partnering with management (founders Valentin Adia and Michael Morris) who rolled a meaningful portion of their equity. Boca Biolistics is a clinical research organization and biobanking/biomaterials company that procures, stores and sells human biospecimens and also provides in-house analytical laboratory services; the capital will support the company’s next phase of growth and capability expansion.
-
October 23, 2022
- Buyer
- Syncona Limited
- Target
- Applied Genetic Technologies Corporation
- Industry
- Biotechnology
- Location
- Florida, United States
- Type
- Buyout
Syncona Limited will acquire Applied Genetic Technologies Corporation (AGTC) via a tender offer, paying $0.34 per share in cash upfront (approximately $23.5 million) with contingent value rights (CVRs) that could provide up to an additional $0.73 per share (up to $50.0 million) for total potential consideration of up to $1.07 per share. The transaction, unanimously approved by AGTC’s board, will take AGTC private and is intended to advance AGTC's retinal gene therapy programs amid funding challenges for the public company.
-
- Buyer
- Medix Biochemica
- Target
- Bioresource Technology (BRT)
- Industry
- Biotechnology
- Location
- Florida, United States
- Type
- Buyout
Medix Biochemica has acquired a 100% stake in US-based Bioresource Technology (BRT) to expand its base matrix capabilities and strengthen its presence in the United States. BRT will be integrated into Medix Biochemica’s IVD Biomaterials Business Unit (St. Louis) while operations continue in Weston, Florida, and BRT leadership will serve as strategic advisors.
-
January 20, 2022
- Buyer
- Blue Water Ventures International, Inc.
- Target
- Psycheceutical, Inc.
- Industry
- Biotechnology
- Location
- Florida, United States
- Type
- Buyout
Blue Water Ventures International, Inc. (BWVI) has completed a merger to acquire Psycheceutical, Inc., making the biotech a wholly-owned subsidiary. BWVI — a publicly-listed company — will pivot its business to focus on psychedelic drug development and intends to provide near-term capital as Psycheceutical advances its delivery technologies toward initial clinical trials.
-
November 13, 2019
- Buyer
- Arranta Bio
- Target
- Captozyme
- Industry
- Biotechnology
- Location
- Florida, United States
- Type
- Addon
Arranta Bio has acquired Captozyme and integrated its Gainesville, Florida team and facilities to create a Center of Excellence for microbiome process and analytical development and early clinical supply. The acquisition expands Arranta's CDMO capabilities for live biotherapeutics and transfers Captozyme's clinical GMP capacity while Captozyme's enzyme therapeutic assets were spun out into Oxidien Pharmaceuticals.
-
- Buyer
- Arcline Investment Management
- Target
- Akron Biotechnology LLC
- Industry
- Biotechnology
- Location
- Florida, United States
- Type
- Buyout
Arcline Investment Management has acquired a majority interest in Akron Biotechnology LLC, a supplier of cGMP-compliant materials and services for cell and gene therapy manufacturers. Akron will remain led by founder and CEO Dr. Claudia Zylberberg, and Arcline plans to expand Akron's manufacturing capacity and pursue complementary acquisitions to build a platform in regenerative medicine.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Frequently Asked Questions
Which acquisitions involve therapeutics development in Florida?
Several deals focus on therapeutic programs or clinical studies, including Telomir’s acquisition of TELI Pharmaceuticals, Inc., Cyclo’s merger forming Cyclo Therapeutics, Inc., and Syncona’s tender offer to take Applied Genetic Technologies Corporation private to advance retinal gene therapy programs.
Do the Florida biotech deals include enabling technology and manufacturing capacity?
Yes. Examples include Branded Legacy’s acquisitions that add proprietary delivery systems and cultivation/lab space, Arranta Bio’s integration of Gainesville facilities to build a microbiome process and analytical development center, and Medix Biochemica’s integration of BRT to expand matrix capabilities.
Are research services and biospecimen-related businesses part of these Florida transactions?
They are. Zephyr AI, Inc. acquired Aster Insights for scientific and clinical intelligence for oncology discovery, and Boca Biolistics is described as a clinical research organization and biobanking/biomaterials company involved with human biospecimens and in-house analytical services.
What deal structures show up most often in the listed transactions?
The page facts show a mix, including all-stock mergers (e.g., Cyclo/AMT), stock consideration in reported terms (e.g., Fifty 1 Labs / Genetic Networks LLC), and a tender offer with contingent value rights (e.g., Syncona / AGTC).
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
Biotechnology Buyers & Acquisitions in Canada
Private Equity-Backed Biotechnology Buyers
Biotechnology Acquisitions in 2026
Biotechnology Acquisitions in 2025
Biotechnology Acquisitions in 2024
Biotechnology Acquisitions in 2023
Biotechnology Acquisitions in 2022
Biotechnology Acquisitions in 2019
Acquisitions in Florida
Private Equity-Backed Acquisitions in Florida
Acquisitions in Florida in 2026